Breaking News

Actinium, IsoTherapeutics In Actimab-A Manufacturing
 Pact

April 7, 2014

To complete studies required for a new manufacturing process

Actinium Pharmaceuticals, Inc. has entered a collaboration with IsoTherapeutics Group to complete studies required for a new manufacturing process for Actimab-A, Actinium's Phase 1/2 trial for newly diagnosed acute myeloid leukemia (AML) patients in a single arm multicenter trial.
 
According to the companies, the newly developed manufacturing process results in a tenfold improvement of manufacturing yield. IsoTherapeutics will perform additional studies to generate the necessary documentation for regulatory submissions.
 
“Alpha particle immunotherapy is a new approach in oncology and for such novel technologies manufacturing development is inextricably linked with clinical development,” said Dr. Kaushik J. Dave, the president and chief executive officer of Actinium Pharmaceuticals. “We are encouraged by the big advancements we are making in both areas and confirmation of our methods from our partners and collaborators. These advances have application beyond any individual drug.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016